ACY-1083 free base · Synonyms: ACY 1083 · ACY1083

ACY-1083 is a selective and brain-penetrating HDAC6 inhibitor.

For research use only. Not for human or veterinary use.

Target HDAC

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

ACY-1083 structure

CAS No.: 1708113-43-2

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
10 mg	USD 430.00	BP-01925-10mg	In stock	Get quote
25 mg	USD 660.00	BP-01925-25mg	In stock	Get quote
50 mg	USD 960.00	BP-01925-50mg	In stock	Get quote
100 mg	USD 1,260.00	BP-01925-100mg	In stock	Get quote
250 mg	USD 1,760.00	BP-01925-250mg	In stock	Get quote
500 mg	Inquire	BP-01925-500mg	Inquire	Inquire
1 g	Inquire	BP-01925-1g	Inquire	Inquire

Need another size or custom synthesis? Request a quote.

Description

ACY-1083 is a selective and brain-penetrating HDAC6 inhibitor with an IC50 of 3 nM and is 260-fold more selective for HDAC6 than all other classes of HDAC isoforms. ACY-1083 effectively reverses chemotherapy-induced peripheral neuropathy.

Biological activity

In Vitro Treatment with ACY-1083 (30 and 300 nM) significantly improves cell viability in a dose-dependent manner. In Vivo ACY-1083 (i.p.; 10 mg/kg; for 7 days) effectively relieves Cisplatin-induced mechanical allodynia in C57BL/6J mice ACY-1083 (oral doses of 3 mg/kg ACY-1083 for 7 days) reverses Paclitaxel-induced mechanical allodynia in adult male SD rats. Mice dosed with 5 mg/kg ACY-1083 by intraperitoneal (i.p.) injection have a maximum plasma concentration (Cmax) of 936 ng/mL, a half-life (T1/2) of 3.5 hours, and a biologically active plasma exposure of 8 hours after dosing.

Identifiers

SMILES: FC(CC1)(F)CCC1(NC2=NC=C(C(NO)=O)C=N2)C3=CC=CC=C3
InChIKey: MRWCVKLVSWYIFO-UHFFFAOYSA-N

Specifications

MW (average): 348.3472
Formula: C₁₇H₁₈F₂N₄O₂
CAS No.: 1708113-43-2
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20°C, stored under nitrogen; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO : 100 mg/mL

Documents

References

[1]. Krukowski K, et al. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain. 2017 Jun;158(6):1126-1137.

[2]. Vahagn C Nikolian, et al. Isoform 6-selective histone deacetylase inhibition reduces lesion size and brain swelling following traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg. 2019 Feb;86(2):232-239.

Same research area

Search Cancer